2024
Race- and Ethnicity-Related Differences in Heart Failure With Preserved Ejection Fraction Using Natural Language Processing
Brown S, Biswas D, Wu J, Ryan M, Bernstein B, Fairhurst N, Kaye G, Baral R, Cannata A, Searle T, Melikian N, Sado D, Lüscher T, Teo J, Dobson R, Bromage D, McDonagh T, Vazir A, Shah A, O’Gallagher K. Race- and Ethnicity-Related Differences in Heart Failure With Preserved Ejection Fraction Using Natural Language Processing. JACC Advances 2024, 3: 101064. PMID: 39050815, PMCID: PMC11268103, DOI: 10.1016/j.jacadv.2024.101064.Peer-Reviewed Original ResearchBlack patientsPro-B-type natriuretic peptide levelsN-terminal pro-B-type natriuretic peptide levelsEuropean Society of Cardiology criteriaDiagnosis of HFpEFNatriuretic peptide levelsHeterogeneous clinical syndromeEuropean SocietyCardiology criteriaHFpEF diagnosisClinical presentationFPEF scoreAsian patientsPatient demographicsEthnicity-related differencesMetabolic comorbiditiesAtrial fibrillationHeart failureHFpEFDiagnostic performancePeptide levelsWhite patientsClinical syndromePatientsQuantify health inequalitiesRacial/Ethnic Disparities in Aortic Valve Replacement Among Medicare Beneficiaries in the United States, 2012-2019
Gupta A, Mori M, Wang Y, Pawar S, Vahl T, Nazif T, Onuma O, Yong C, Sharma R, Kirtane A, Forrest J, George I, Kodali S, Chikwe J, Geirsson A, Makkar R, Leon M, Krumholz H. Racial/Ethnic Disparities in Aortic Valve Replacement Among Medicare Beneficiaries in the United States, 2012-2019. The American Journal Of Medicine 2024, 137: 321-330.e7. PMID: 38190959, PMCID: PMC11019903, DOI: 10.1016/j.amjmed.2023.12.026.Peer-Reviewed Original ResearchAortic valve replacementRace/ethnicityValve replacementAortic stenosisWhite patientsMedicare beneficiariesSurgical aortic valve replacement (SAVR) proceduresCross-sectional cohort studyAortic valve replacement proceduresAortic stenosis treatmentRacial/ethnic disparitiesValve replacement proceduresSelf-reported race/ethnicityRace-related differencesIndex admissionIndex hospitalizationCohort studyAsian patientsPrincipal diagnosisProcedural outcomesStenosis treatmentCare spectrumPatientsEthnic disparitiesStenosis
2023
Abstract 18205: Ethnicity and Aortic Stenosis: Presentation, Management and Outcomes
Biswas D, Wu J, Bharucha A, Fairhurst N, Kaye G, Baghai M, Dworakowski R, Byrne J, MacCarthy P, Shah A, Eskandari M, O'Gallagher K. Abstract 18205: Ethnicity and Aortic Stenosis: Presentation, Management and Outcomes. Circulation 2023, 148: a18205-a18205. DOI: 10.1161/circ.148.suppl_1.18205.Peer-Reviewed Original ResearchAortic valve replacementTranscatheter aortic valve implantationAsian patientsWhite patientsBlack patientsSevere ASAortic stenosisBenefit of transcatheter aortic valve implantationSurgical aortic valve replacementManagement of aortic stenosisCox multivariate analysisSocial deprivationManagement of ASAortic valve implantationTAVI interventionKing's College HospitalEthnicity-based differencesValve replacementCardiac symptomsCollege HospitalElectronic health recordsMortality benefitValve implantationMultivariate analysisAS diagnosis82P NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
Choo J, Jeraj S, Chan G, Sundar R, Yong W, Lee M, Ngoi N, Wong A, Soo R, Chee C, Lim J, Goh B, Lee S, Tan D. 82P NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies. Annals Of Oncology 2023, 34: s1498. DOI: 10.1016/j.annonc.2023.10.217.Peer-Reviewed Original ResearchTERT Promoter Mutations Frequency Across Race, Sex, and Cancer Type
Zarif T, Machaalani M, Nawfal R, Nassar A, Xie W, Choueiri T, Pomerantz M. TERT Promoter Mutations Frequency Across Race, Sex, and Cancer Type. The Oncologist 2023, 29: 8-14. PMID: 37462445, PMCID: PMC10769781, DOI: 10.1093/oncolo/oyad208.Peer-Reviewed Original ResearchConceptsTelomerase reverse transcriptase promoter mutationHead and neck cancerTelomerase reverse transcriptaseTERT promoter mutationsPromoter mutationsTelomerase reverse transcriptase gene promoter mutationsClinical trialsWhite patientsCancer typesImmune checkpoint inhibitorsCheckpoint inhibitorsPatient self-reportAsian patientsNeck cancerThyroid cancerPatient selectionBlack patientsNext-generation sequencingPatientsObservational studyCancerCancer biologyMutation frequencyMelanomaReverse transcriptaseComparative genomics between matched solid and lepidic portions of semi-solid lung adenocarcinomas
Woodard G, Ding V, Cho C, Brand N, Kratz J, Jones K, Jablons D. Comparative genomics between matched solid and lepidic portions of semi-solid lung adenocarcinomas. Lung Cancer 2023, 180: 107211. PMID: 37121213, PMCID: PMC10900430, DOI: 10.1016/j.lungcan.2023.107211.Peer-Reviewed Original ResearchConceptsInvasive portionDriver mutationsSolid adenocarcinomaLung cancer driver mutationsNext-generation sequencingWarrants further studyLobar resectionClinical characteristicsSurgical databaseAsian patientsInvasive cancerPoor prognosisLung cancerLung lesionsInvasive componentInvasive solid tumorsNormal lungLepidicStage IPromising biomarkerSolid tumorsCancer developmentSame time periodGenes SPP1Gene expressionAssociations between patient sociodemographic factors and non-treatment for localized prostate cancer.
Novosel M, Smani S, Marks V, Jeong F, Sprenkle P, Leapman M. Associations between patient sociodemographic factors and non-treatment for localized prostate cancer. Journal Of Clinical Oncology 2023, 41: 307-307. DOI: 10.1200/jco.2023.41.6_suppl.307.Peer-Reviewed Original ResearchHigh-risk prostate cancerLocalized prostate cancerAggressive prostate cancerProstate cancerWhite patientsLower oddsDefinitive treatmentRisk strataSociodemographic factorsMean patient ageNational Cancer DatabaseHigh-risk diseasePatient sociodemographic factorsMultivariable logistic regressionClinical risk criteriaPatient ageImproved survivalBlack patientsInitial treatmentRisk diseaseAsian patientsRetrospective studyBlack raceInsurance statusPatient raceClinical outcome and prognostic factors for Asian patients in Phase I clinical trials
Loh J, Wu J, Chieng J, Chan A, Yong W, Sundar R, Lee S, Wong A, Lim J, Tan D, Soo R, Goh B, Tai B, Chee C. Clinical outcome and prognostic factors for Asian patients in Phase I clinical trials. British Journal Of Cancer 2023, 128: 1514-1520. PMID: 36797357, PMCID: PMC10070409, DOI: 10.1038/s41416-023-02193-2.Peer-Reviewed Original ResearchConceptsNeutrophil-lymphocyte ratioRoyal Marsden HospitalPhase I studyPhase I clinical trialPoor ECOG statusPre-treated patientsPrimary tumor sitePhase I populationLonger-term survivalECOG statusPrognostic factorsPrognostic scoreRetrospective reviewTumor siteAsian patientsSolid tumorsClinical outcomesPoor prognosisBackgroundPatient selectionPrognostic abilityPrognostic modelPatientsPrognosisIncreased scoresScoresTrends in the likelihood of receiving percutaneous coronary intervention in a low-volume hospital and disparities by sociodemographic communities
Wang C, Lindquist K, Krumholz H, Hsia R. Trends in the likelihood of receiving percutaneous coronary intervention in a low-volume hospital and disparities by sociodemographic communities. PLOS ONE 2023, 18: e0279905. PMID: 36652416, PMCID: PMC9847957, DOI: 10.1371/journal.pone.0279905.Peer-Reviewed Original ResearchConceptsLow-volume hospitalsNon-Latinx WhitesRelative riskSociodemographic groupsLow-income zip codesHospital PCI volumeRetrospective cohort studyPercutaneous coronary interventionCoronary artery diseaseLow-volume centersFavorable patient outcomesLow-volume facilitiesZip code median incomeLow incomeRace/ethnicityCohort studyCoronary interventionLatinx patientsSecondary outcomesArtery diseasePCI centerPrimary outcomePCI volumeAsian patientsCertain socioeconomic factors
2022
Contemporary US Trends In Heart Transplantation And LVAD Index Hospitalizations: Volumes Increase, Utilization And Cost Vary Over Time, 2015-2018
Clark K, Reinhardt S, Chouairi F, Miller E, Kay B, Fuery M, Guha A, Ahmad T, Desai N. Contemporary US Trends In Heart Transplantation And LVAD Index Hospitalizations: Volumes Increase, Utilization And Cost Vary Over Time, 2015-2018. Journal Of Cardiac Failure 2022, 28: s65. DOI: 10.1016/j.cardfail.2022.03.165.Peer-Reviewed Original ResearchLength of stayHeart transplantationHospital mortalityIndex hospitalizationLVAD implantationLonger median LOSMedian LOSLonger LOSPost-discharge utilizationNational Inpatient SampleHospitalization volumeInpatient mortalityHispanic patientsAsian patientsInpatient SampleHospitalizationMortalityStudy periodUS trendsPatientsTransplantationAdmissionLVADImplantationHigh percentageEffects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
Docherty K, Anand I, Chiang C, Chopra V, Desai A, Kitakaze M, Verma S, Vinh P, Inzucchi S, Køber L, Kosiborod M, Martinez F, Bengtsson O, Ponikowski P, Sabatine M, Sjöstrand M, Solomon S, Langkilde A, Jhund P, McMurray J. Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. JACC Asia 2022, 2: 139-153. PMID: 36339117, PMCID: PMC9627879, DOI: 10.1016/j.jacasi.2022.02.004.Peer-Reviewed Original ResearchDAPA-HF trialReduced ejection fractionEjection fractionCardiovascular deathAsian patientsHF eventsElevated N-terminal pro-B-type natriuretic peptideNew York Heart Association functional class IIN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideLeft ventricular ejection fractionSafety of dapagliflozinFunctional class IIEffect of dapagliflozinVentricular ejection fractionDAPA-HFDrug discontinuationHFrEF patientsPrimary endpointAdverse eventsHeart failurePrespecified outcomesPrimary outcomeNatriuretic peptideSame extentTemporal Trends in Racial and Ethnic Disparities in Endovascular Therapy in Acute Ischemic Stroke
Sheriff F, Xu H, Maud A, Gupta V, Vellipuram A, Fonarow G, Matsouaka R, Xian Y, Reeves M, Smith E, Saver J, Rodriguez G, Cruz‐Flores S, Schwamm L. Temporal Trends in Racial and Ethnic Disparities in Endovascular Therapy in Acute Ischemic Stroke. Journal Of The American Heart Association 2022, 11: e023212. PMID: 35229659, PMCID: PMC9075329, DOI: 10.1161/jaha.121.023212.Peer-Reviewed Original ResearchConceptsAcute ischemic strokeEndovascular therapyEVT useIschemic strokeNon-Hispanic white patientsGuidelines-Stroke databaseHealth Stroke ScaleMortality/dischargeClinical trial publicationsPatient disparitiesDischarge homeEligible patientsNHW patientsStroke ScaleWhite patientsBlack patientsAsian patientsFunctional outcomeLarge cohortTrial publicationsPatientsFunctional independenceEthnic disparitiesRelated outcomesNational InstituteRace-Ethnic Disparities in Rates of Declination of Thrombolysis for Stroke
Mendelson S, Zhang S, Matsouaka R, Xian Y, Shah S, Lytle B, Solomon N, Schwamm L, Smith E, Saver J, Fonarow G, Holl J, Prabhakaran S. Race-Ethnic Disparities in Rates of Declination of Thrombolysis for Stroke. Neurology 2022, 98: e1596-e1604. PMID: 35228335, PMCID: PMC9052571, DOI: 10.1212/wnl.0000000000200138.Peer-Reviewed Original ResearchConceptsTissue plasminogen activatorNon-Hispanic black patientsTPA-eligible patientsRace/ethnicityBlack patientsNon-Hispanic black race/ethnicityNon-Hispanic white patientsBlack race/ethnicityAsian race/ethnicityGuidelines-Stroke registryPrimary stroke centerSingle-center studyMultivariable logistic regressionRace-ethnic disparitiesNon-Hispanic whitesEligible patientsHospital factorsNationwide registryPatient demographicsStroke centersSymptom onsetWhite patientsMultivariable analysisStroke careAsian patientsA phase 1 study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of the selective inhibitor of nuclear export (SINE) selinexor in Asian patients with advanced or metastatic malignancies
Ho J, Heong V, Yong W, Soo R, Chee C, Wong A, Sundar R, Thian Y, Gopinathan A, Pang M, Koe P, Jeraj S, Soe P, Soe M, Tang T, Ng M, Tai D, Tan T, Xu H, Chang H, Landesman Y, Shah J, Shacham S, Lee S, Tan D, Goh B, Tan D. A phase 1 study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of the selective inhibitor of nuclear export (SINE) selinexor in Asian patients with advanced or metastatic malignancies. Therapeutic Advances In Medical Oncology 2022, 14: 17588359221087555. PMID: 35432603, PMCID: PMC9008867, DOI: 10.1177/17588359221087555.Peer-Reviewed Original ResearchPhase 1 studyAsian patientsMetastatic malignancyMedian t<sub>max</sub> wasGrade 3 adverse eventsNCI Common Terminology CriteriaRecommended phase 2 doseAsian patient cohortContinuous dosing regimensGrade 3 fatiguePhase 2 doseThymic carcinoma patientsDose-escalation designCommon Terminology CriteriaInhibitor of nuclear exportCytoplasmic localization of p27Dose expansionComplete responseHodgkin lymphomaExpansion cohortLymphoma patientsPartial responseDrug holidayEscalation designPharmacodynamic assessments
2021
DIAPH1 Variants in Non–East Asian Patients With Sporadic Moyamoya Disease
Kundishora AJ, Peters ST, Pinard A, Duran D, Panchagnula S, Barak T, Miyagishima DF, Dong W, Smith H, Ocken J, Dunbar A, Nelson-Williams C, Haider S, Walker RL, Li B, Zhao H, Thumkeo D, Marlier A, Duy PQ, Diab NS, Reeves BC, Robert SM, Sujijantarat N, Stratman AN, Chen YH, Zhao S, Roszko I, Lu Q, Zhang B, Mane S, Castaldi C, López-Giráldez F, Knight JR, Bamshad MJ, Nickerson DA, Geschwind DH, Chen SL, Storm PB, Diluna ML, Matouk CC, Orbach DB, Alper SL, Smith ER, Lifton RP, Gunel M, Milewicz DM, Jin SC, Kahle KT. DIAPH1 Variants in Non–East Asian Patients With Sporadic Moyamoya Disease. JAMA Neurology 2021, 78: 993-1003. PMID: 34125151, PMCID: PMC8204259, DOI: 10.1001/jamaneurol.2021.1681.Peer-Reviewed Original ResearchConceptsSporadic moyamoya diseaseMoyamoya diseaseValidation cohortDiscovery cohortIntracranial internal carotid arteryRisk genesBilateral moyamoya diseaseTransfusion-dependent thrombocytopeniaLarger validation cohortNon-East Asian patientsInternal carotid arteryAsian individualsCompound heterozygous variantsNon-East AsiansProgressive vasculopathyTransmitted variantsAsian patientsChildhood strokeMedical recordsCarotid arteryTherapeutic ramificationsMAIN OUTCOMEMouse brain tissuePatientsUS hospitalsDisparities in ART Live Birth and Cumulative Live Birth Outcomes for Hispanic and Asian Women Compared to White Non-Hispanic Women
Kotlyar AM, Simsek B, Seifer DB. Disparities in ART Live Birth and Cumulative Live Birth Outcomes for Hispanic and Asian Women Compared to White Non-Hispanic Women. Journal Of Clinical Medicine 2021, 10: 2615. PMID: 34198545, PMCID: PMC8231797, DOI: 10.3390/jcm10122615.Peer-Reviewed Original ResearchCumulative live birth rateNon-Hispanic womenLive birthsWNH womenAsian womenWhite non-Hispanic womenART live birthsCycles of ARTHistory of endometriosisIndependent prognostic factorLive birth rateReproductive technology outcomesEtiology of infertilityLive birth outcomesMultivariate logistic regressionUse of ICSINumber of embryosNulliparous womenPrognostic factorsBirth outcomesAsian patientsART cyclesART treatmentART statusMember clinicsLow‐dose pembrolizumab in the treatment of advanced non‐small cell lung cancer
Low J, Huang Y, Sooi K, Ang Y, Chan Z, Spencer K, Jeyasekharan A, Sundar R, Goh B, Soo R, Yong W. Low‐dose pembrolizumab in the treatment of advanced non‐small cell lung cancer. International Journal Of Cancer 2021, 149: 169-176. PMID: 33634869, PMCID: PMC9545741, DOI: 10.1002/ijc.33534.Peer-Reviewed Original ResearchConceptsAdvanced non-small cell lung cancerNon-small cell lung cancerProgression-free survivalCell lung cancerFood and Drug AdministrationOverall survivalTreatment of advanced non-small cell lung cancerLung cancerDose of pembrolizumabImmune-related toxicitiesEffectiveness of pembrolizumabWeight-based dosingRetrospective observational studyNational University HospitalDegrees of cost savingsCost-minimisation analysisFixed doseSurvival outcomesAsian patientsNo significant differencePembrolizumabOncogenic driversSingle agentLow dosesRandomised trials40P Phase I study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of selinexor in Asian patients with advanced solid tumour malignancies
Ho J, Heong V, Yong W, Soo R, Chee C, Wong A, Thian Y, Sundar R, Gopinathan A, Lee S, Goh B, Xu H, Tan D. 40P Phase I study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of selinexor in Asian patients with advanced solid tumour malignancies. Annals Of Oncology 2021, 32: s17. DOI: 10.1016/j.annonc.2021.01.055.Peer-Reviewed Original Research
2020
Racial Disparity Between Asian and Caucasian Crouzon Syndrome in Skull Morphology.
Lu X, Forte AJ, Fan F, Zhang Z, Teng L, Yang B, Alperovich M, Steinbacher DM, Alonso N, Persing JA. Racial Disparity Between Asian and Caucasian Crouzon Syndrome in Skull Morphology. Journal Of Craniofacial Surgery 2020, 31: 2182-2187. PMID: 33136851, DOI: 10.1097/scs.0000000000006741.Peer-Reviewed Original ResearchConceptsCrouzon patientsCrouzon syndromeLateral pterygoidIntracranial sideRacial disparitiesDifferent patient populationsPosterior fossa volumeCranial basePosterior cranial fossaMiddle cranial baseAsian patientsCaucasian patientsPatient populationTomographic scanPatientsCranial base angleCranial base angulationCranial fossaFossa volumeTreatment planRacial disparities in surgical outcomes for benign thyroid disease
Maduka RC, Gibson CE, Chiu AS, Jean RA, Wills-Johnson N, Azar SA, Oliveira K, Ahuja V. Racial disparities in surgical outcomes for benign thyroid disease. The American Journal Of Surgery 2020, 220: 1219-1224. PMID: 32669203, DOI: 10.1016/j.amjsurg.2020.06.054.Peer-Reviewed Original ResearchConceptsBenign thyroid diseaseThyroid diseaseRLN injuryNeck hematomaPostoperative complicationsWhite patientsSurgical outcomesRacial disparitiesRecurrent laryngeal nerve injuryLaryngeal nerve injurySignificant postoperative complicationsMalignant thyroid diseaseSignificant hypocalcemiaNerve injuryPostoperative outcomesPatient factorsSurgical treatmentBlack patientsAsian patientsBenign diseaseThyroid surgeryHigh incidenceGreater oddsPatientsMultivariate analysis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply